For BRAF mutations, there is a need to further explore considerations of PD-L1 as a biomarker and sequencing of immunotherapy with BRAF therapy of choice to improve response rate, citing a recent RW study by Gibson et al.43 that revealed how both dual BRAF/MEK inhibition and immunotherapy-based regimens have evidence of benefit in BRAF-mutated NSCLC. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.